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Abstract Lasmiditan is a novel selective 5-HT1F receptor
agonist. It is both scientiﬁcally and clinically relevant to
review whether a 5-HT1F receptor agonist is effective in the
acute treatment of migraine. Two RCTs in the phase II
development of lasmiditan was reviewed. In the intravenous
placebo-controlledRCT,lasmiditandosesof2.5–45 mgwere
used, and there was a linear association between headache
relief (HR) rates and dose levels (P\0.02). For lasmiditan
20 mg,HRwas64 %andforplaceboitwas45 %(NS).Inthe
oralplacebo-controlledRCT,lasmiditandosesof50,100,200
and 400 mg were used. For HR, all doses of lasmiditan were
superior to placebo (P\0.05). For lasmiditan 400 mg, HR
was64 %anditwas25 %forplacebo.Adverseevents(AEs)
emerging from the treatment were reported by 22 % of the
patients receiving placebo and by 65, 73, 87 and 87 % of
patientsreceiving50,100,200and400 mg,respectively.The
majority of AEs after lasmiditan 100 and 400 mg were
moderate or severe. For the understanding of migraine path-
ophysiology, it is very important to note that a selective
5-HT1F receptor agonist like lasmiditan is effective in the
acute treatment of migraine. Thus, migraine can be treated
with a drug that has no vasoconstrictor ability. While
lasmiditanmostlikelyiseffectiveinthetreatmentofmigraine
attacks it had, unfortunately, a high incidence of CNS related
AEsintheoralRCT.IfconﬁrmedinlargerstudiesinphaseIII,
this might adversely limit the use of this highly speciﬁc non-
vascularacutetreatmentofmigraine.Largerstudiesincluding
the parameters of patients’ preferences are necessary to
accurately position this new treatment principle in relation to
the triptans.
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Introduction
The pathophysiology of migraine is incompletely under-
stood. Previously, extracranial dilatation was considered
pivotal in causing migraine headache [1]. The selective
5-HT1B/1D receptor agonists, triptans, were developed as
relatively selective cranial vasoconstrictors based on the
efﬁcacy on the 5-HT1B receptor [2, 3]. This receptor is also
present in non-cranial vasculature [4, 5] and the triptans
carry the risk of causing coronary vasoconstriction [4]. The
triptans are thus contraindicated in patients with cardio-
and cerebrovascular disease. The CGRP antagonists,
olcegepant [6], telcagepant [7], BI 44370 TA [8] and MK-
3207 [9] were developed for migraine as drugs devoid of
general vasoconstrictor activity [10]. They were effective
in the acute treatment of migraine [6, 7], but the devel-
opments were stopped for various reasons [11].
Ithasbeensuggestedthatcranialvasodilatation,observed
previously [12] and quite recently [13], is not the primary
nociceptivestimulusformigraineheadache[14,15],andthat
neural inhibition of trigeminal pathways could provide an
alternative non-vascular antimigraine mechanism [15].
Preclinical pharmacological proﬁle of lasmiditan [16]
In vitro binding studies of lasmiditan showed a Ki value of
2.2 nM at the 5-HT1F receptor, compared with Ki values of
1,043 and 1,357 nM at the 5-HT1B and 5-HT1D receptors,
respectively, which is a selectivity ratio [470-fold [16].
Unlike sumatriptan, a 5-HT1B/1D receptor agonist, lasmiditan
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up to 100 lM[ 16]. In two rodents models with presumed
relevance for migraine (dural plasma extravasation, and
induction of the immediate early gene c-Fos in the tri-
geminal nucleus caudalis), oral administration of lasmid-
itan potently inhibited these markers associated with
electrical stimulation of the trigeminal ganglion [16]. The
oral bioavailability of lasmiditan is 40 % and the Tmax is
2 h (CoLucid Pharmaceuticals, data on ﬁle).
Review of phase II trials
Lasmiditan has so far been investigated in two RCTs: one
with intravenous [15], and one with oral administration
[17] of the drug.
The intravenous RCT was a randomised, multicentre,
double-blind, placebo-controlled, group-sequential, adap-
tive treatment-assignment, proof-of-concept and dose-
ﬁnding study [15]. The investigators treated 130 in-hospital
migraine patients with moderate or severe headache. The
patients were allocated to a range of intravenous dose
levels of lasmiditan or placebo in small cohorts (n = 5–6).
The starting dose was 2.5 mg. Subsequent doses were
adjusted up and down according to the efﬁcacy and safety
observed in the preceding cohort. The primary efﬁcacy
measure was headache relief (a decrease in headache from
moderate or severe to none or mild) at 2 h.
A total of 88 patients received lasmiditan in doses of
2.5–45 mg, and 42 received placebo. The study was ter-
minated when the 20 mg dose met predeﬁned efﬁcacy
stopping rules [15]. As illustrated in Fig. 1 there was a
linear association between response rates and dose level
(P = 0.0126) [15]. For lasmiditan 20 mg, the headache
relief was 64 % and for placebo it was 45 %. Thus, the
therapeutic gain (percentage difference between active
drug and placebo) was 19 % (95 % CI -4 to 42 %).
Adverse events were generally mild and were reported by
65 % of patients on lasmiditan and 43 % on placebo [15].
The oral RCT with lasmiditan was a randomised, double-
blind, placebo-controlled, parallel-group study [17]. Patients
were randomized to oral lasmiditan (50, 100, 200 or
400 mg) or placebo in a 1:1:1:1.1 ratio. Out of 534
screened and randomized patients, 391 treated a migraine
attack and 378 patients qualiﬁed for the primary modiﬁed
intent-to-treat analysis [17]. Patients treated moderate or
severe migraine headache, and the primary efﬁcacy mea-
sure was headache relief (HR) 2 h after drug administration
(see Fig. 2; Table 1). Headache response for all doses of
lasmiditan was superior to placebo (P\0.05) (Fig. 2). For
lasmiditan 400 mg, the therapeutic gain was 38 % (95 %
CI 28–51 %) (Table 1). Adverse events emerging from the
treatment were reported by 22 % of the patients receiving
placebo and by 65, 73, 87 and 87 % of patients receiving
50, 100, 200 and 400 mg lasmiditan, respectively [17]. The
AEs for placebo and lasmiditan 100 and 400 mg are shown
in Table 2. The distribution of intensity of AEs after pla-
cebo and oral lasmiditan 100 and 400 mg is shown in
Table 3. The majority of AEs after placebo were mild
(15 %) or moderate (13 %), whereas the majority of AEs
after lasmiditan were moderate [46 % (100 mg), 60 %
(400 mg)] or severe [27 % (100 mg), 44 % (400 mg)]
[CoLucid Pharmaceuticals, data on ﬁle].
Discussion
The intravenous randomised controlled trial of lasmiditan
[15] should be considered as a proof-of-concept study
validating the principle of 5-HT1F receptor agonism in the
Fig. 1 Proportion of migraine patients with headache relief (a
decrease of headache from moderate or severe to none or mild)
(HR) at 2 h after intravenous lasmiditan (PBO placebo) [15]
Fig. 2 Proportion of migraine patients with HR at 2 h after oral
lasmiditan 50–400 mg (PBO placebo). *P\0.05 [17]
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onstrate superiority of the individual doses of lasmiditan to
placebo (see Fig. 1). The oral study [17] documented
beyond doubt that 5-HT1F agonism is highly effective
(Fig. 2), perhaps as effective as the triptans. Usually one
would expect an intravenous administration of a drug to be
more effective and cause more adverse events (AEs) than
the oral form of the drug. With lasmiditan, the case was the
opposite: oral administration is better than the intravenous
administration as judged from the therapeutic gains which
were 38 and 19 %, respectively (Table 1). The reason for
these results is most likely a relatively low intravenous
dose of 20 mg lasmiditan. The oral dose of lasmiditan was
400 mg and the oral bioavailability of lasmiditan is 40 %
(CoLucid Pharmaceuticals, data on ﬁle). Thus, an oral dose
of 400 mg corresponds to an intravenous dose of 160 mg
far above the doses (2.5–45 mg) used in the intravenous
RCTs. A high placebo response with intravenous treatment
may, however, also diminish the TG. Therefore, the
absolute response is also important and for oral lasmiditan
it was similar to previous results with oral triptans.
Adverse events should also be evaluated by their abso-
lute size and by subtracting the AEs after placebo from
AEs after active drug. For oral lasmiditan 400 mg, the
placebo-subtracted AEs rate is 62 % [number needed to
harm (NNH) 1.6]. For intravenous lasmiditan 20 mg the
placebo-subtracted AEs is 25 % (NNH 4). Thus, oral
lasmiditan 400 mg caused more AEs than the intravenous
dose of 20 mg as would be expected from the higher dose
absorbed with the oral 400 mg dose. For the standard
triptan, sumatriptan 100 mg, the placebo-subtracted AEs
rate is 16 % (NNH 6.3) [18].
The high incidence of AEs for lasmiditan is of potential
concern, but needs further evaluation due to small num-
bers. In future RCTs, one should include also a global
evaluation of study medication, such as excellent, very
good, good, neither good nor bad, poor, very poor and
extremely poor [8]. This would allow an estimation of how
patients really rate the recorded adverse events.
The results seem to suggest that a dose of 100 mg might
be preferable to 400 mg because apparently it had the same
efﬁcacy in terms of headache relief (see Fig. 2). This
would, however, only result in a minor decrease in AEs to
73 %. Paradoxically, the pain-free response at 2 h was
considerably smaller with 100 than with 400 mg. If this is
real and not just due to statistical ﬂuctuation, pain-free
response would decrease from 28 (lasmiditan 400 mg) to
14 % (lasmiditan 100 mg) [17]. Migraine patients want to
be pain free [19] and 14 % pain free is too low for a drug to
be successful in our opinion. Again, more studies with
higher numbers are necessary to answer these questions.
The effect of intravenous lasmiditan should be compared
to the current standard triptan, sumatriptan, as illustrated in
Table 1. The therapeutic gain (TG) (percentage difference
Table 1 Headache relief after intravenous and oral lasmiditan, subcutaneous and oral sumatriptan, and oral LY334370 in randomised, clinical
trials (RCTs) [7, 15, 17, 20]
Drug Headache relief
for active drug
at 2 h (%)
Headache relief
for placebo at
2 h (%)
Therapeutic gain
(95 % conﬁdence
intervals) (%)
NNT (number
needed to treat)
Intravenous lasmiditan 20 mg [15] 6 44 51 9 ( -4t o4 2% )
a 5.3
Oral lasmiditan 400 mg [17] 64 25 38 (28 to 51 %) 2.6
Subcutaneous sumatriptan 6 mg [7] 69 19 51 (48 to 53 %) 2.0
Oral sumatriptan 100 mg [7] 61 28 33 (31 to 35 %) 3.0
LY334370 200 mg [20] 71 19 52 (27 to 77 %) 2.0
a The RCT did not have the power to compare the single doses of lasmiditan with placebo
Table 2 Adverse events with an incidence [5 % of patients in any
dose group [17]
Adverse event Placebo
(%)
Lasmiditan
100 mg (%)
Lasmiditan
400 mg (%)
Dizziness 1 28 37
Fatigue 2 21 24
Vertigo 1 15 24
Somnolence 2 12 11
Paraesthesia 2 11 20
Heaviness 1 5 7
Nausea 0 11 7
Table 3 Adverse events by intensity after placebo and oral lasmid-
itan 100 and 400 mg (CoLucid Pharmaceuticals, data on ﬁle)
Intensity of
adverse events
Placebo
(n = 86)
Lasmiditan
100 mg
(n = 82)
Lasmiditan
400 mg
(n = 70)
Mild 14 (16 %) 35 (43 %) 21(30 %)
Moderate 11 (13 %) 38 (46 %) 42 (60 %)
Severe 5 (6 %) 22 (27 %) 31 (44 %)
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123between active drug and placebo) for intravenous lasmid-
itan 20 mg was 19 % (95 % CI -4 to 42 %) and it was
51 % (95 % CI 48–53 %) for subcutaneous sumatriptan
6m g[ 18]. This lower response for intravenous lasmiditan
compared with subcutaneous sumatriptan probably reﬂects
the low dose of intravenous lasmiditan.
The oral administration of lasmiditan 400 mg should be
compared to the standard triptan, sumatriptan 100 mg, and
the previously investigated 5-HT1F receptor agonist
LY334370 200 mg [19]. The TG for lasmiditan (n = 156)
was 38 % (95 % CI 28–51 %) comparable to the TG of
33 % (95 % CI 31–35 %) for oral sumatriptan (n = 5,072)
[18]. The TG for 5-HT1F receptor agonist LY334370
200 mg (n = 47) was 52 % (95 % CI 27–77 %) (Table 1)
[20] and apparently higher than the two other oral drugs.
However, as few patients were included in RCTs of
lasmiditan and LY334370 resulted in very wide conﬁdence
intervals; therefore, superiority as compared with suma-
triptan should not be claimed.
For the understanding of migraine pathophysiology, it is
very important to note that a selective 5-HT1F receptor
agonist like lasmiditan is effective in the acute treatment of
migraine. This is supported by the previous results with the
other5-HT1Freceptoragonist,LY333470[20](seeTable 1).
Thus, migraine attacks can be treated with a drug that has no
vasoconstrictor ability (it remains to be seen if vasocon-
striction of vessels dilated because of a migraine attack does
occur). The 5-HT1F effect may take place at the perivascular
trigeminal nerve terminals, which will be stabilized and less
likely to leak vasoactive and potentially nociceptive signal-
ling molecules. However, Burstein’s group has shown that
thismechanismisunimportantwiththetriptanswhichrather
seem to work by blocking nociceptive transmission at the
ﬁrstsynapseinthetrigeminalnucleuscaudalis[21].Itseems
likely that the same is the case for 5-HT1F receptor agonists.
Seemingly, this would support the neural theory of migraine
[14]. However, blocking the trigeminovascular system
would also be effective if peripheral nociception was the
primary cause of headache [22].
In conclusion, the 5-HT1F receptor agonist lasmiditan is
effective in the acute treatment of migraine. Unfortunately,
it has a high incidence of CNS-related side effects. If
conﬁrmed in larger studies, this might adversely affect the
uptake of this highly speciﬁc non-vascular acute treatment.
Larger studies including the parameters of patients’ pref-
erences are necessary to accurately position this new
treatment principle in relation to the triptans.
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